TY - JOUR
T1 - Imaging the D3 dopamine receptor across behavioral and drug addictions
T2 - Positron emission tomography studies with [11C]-(+)-PHNO
AU - Boileau, Isabelle
AU - Nakajima, Shinichiro
AU - Payer, Doris
N1 - Funding Information:
Funding for this study was provided by the National Institute of Health/National Institute on Drug abuse (NIH/NIDA; 1R21DA033515-01) (Le Foll, Boileau) and by the Canadian Institute of Health Research (CIHR; MOP 102731); the NIH/NIDA and CIHR had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Dr. Nakajima has received fellowship grants from the CIHR and Japan Society for the Promotion of Science, and manuscript fees from Dainippon Sumitomo Pharma and Kyowa Hakko Kirin.
Publisher Copyright:
© 2015 Elsevier B.V. and ECNP.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Chronic drug use has been associated with dopaminergic abnormalities, detectable in humans with positron emission tomography (PET). Among these, a hallmark feature is low D2 dopamine receptor availability, which has been linked to clinical outcomes, but has not yet translated into a therapeutic strategy. The D3 dopamine receptor on the other hand has gained increasing attention, as, in contrast to D2, chronic exposure to drugs has been shown to up-regulate this receptor subtype in preclinical models of addiction-a phenomenon linked to dopamine system sensitization and drug-seeking. The present article summarizes the literature to date in humans, suggesting that the D3 receptor may indeed contribute to core features of addiction such as impulsiveness and cognitive impairment. A particularly useful tool in investigating this question is the PET imaging probe [11C]-(+)-PHNO, which binds to D2/3 dopamine receptors but has preferential affinity for D3. This technique has been used to demonstrate D3 up-regulation in humans, and can be applied to assess pharmacological interventions for development of D3-targeted strategies in addiction treatment.
AB - Chronic drug use has been associated with dopaminergic abnormalities, detectable in humans with positron emission tomography (PET). Among these, a hallmark feature is low D2 dopamine receptor availability, which has been linked to clinical outcomes, but has not yet translated into a therapeutic strategy. The D3 dopamine receptor on the other hand has gained increasing attention, as, in contrast to D2, chronic exposure to drugs has been shown to up-regulate this receptor subtype in preclinical models of addiction-a phenomenon linked to dopamine system sensitization and drug-seeking. The present article summarizes the literature to date in humans, suggesting that the D3 receptor may indeed contribute to core features of addiction such as impulsiveness and cognitive impairment. A particularly useful tool in investigating this question is the PET imaging probe [11C]-(+)-PHNO, which binds to D2/3 dopamine receptors but has preferential affinity for D3. This technique has been used to demonstrate D3 up-regulation in humans, and can be applied to assess pharmacological interventions for development of D3-targeted strategies in addiction treatment.
KW - Addiction
KW - D dopamine receptor
KW - Impulsiveness
KW - Positron emission tomography
KW - [C]-(+)-PHNO
UR - http://www.scopus.com/inward/record.url?scp=84941314121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941314121&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2015.06.002
DO - 10.1016/j.euroneuro.2015.06.002
M3 - Article
C2 - 26141509
AN - SCOPUS:84941314121
SN - 0924-977X
VL - 25
SP - 1410
EP - 1420
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 9
ER -